Brazil tears up Abbott deal, threatens to violate Kaletra patent

Brazil is again threatening to break Abbott's patent on Kaletra if it won't offer the country a deeper discount on the AIDS drug. Several Brazilian labs have reported to the government that they can manufacture and sell Kaletra for 41 cents per pill, far less than the $1.17 per pill that Abbott charges. A spokesperson for Abbott said the company had thought that it had already struck a fair deal to discount Kaletra, an antiretroviral, but that the company would continue to negotiate in good faith.

- read this article in The New York Times for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.